×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TFFP – tff pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TFFP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
04:15 pm
tffp
TFF Pharmaceuticals Announces It Will Wind Down Operations
High
Report
TFF Pharmaceuticals Announces It Will Wind Down Operations
10/8
01:37 pm
tffp
TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why [Yahoo! Finance]
Medium
Report
TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why [Yahoo! Finance]
9/26
07:00 am
tffp
TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery
High
Report
TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery
9/11
08:23 am
tffp
TFF Pharmaceuticals enters pact for dry powder mRNA-based Covid treatment [Seeking Alpha]
Low
Report
TFF Pharmaceuticals enters pact for dry powder mRNA-based Covid treatment [Seeking Alpha]
9/11
07:00 am
tffp
TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID
High
Report
TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID
9/10
07:00 am
tffp
TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
Neutral
Report
TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
9/3
08:00 am
tffp
TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
High
Report
TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/20
05:00 pm
tffp
Form 10-Q TFF Pharmaceuticals, For: Sep 30
Low
Report
Form 10-Q TFF Pharmaceuticals, For: Sep 30
11/19
04:06 pm
tffp
Form SC 13G/A TFF Pharmaceuticals, Filed by: Carlson Capital, L.P.
Medium
Report
Form SC 13G/A TFF Pharmaceuticals, Filed by: Carlson Capital, L.P.
11/14
04:24 pm
tffp
Form NT 10-Q TFF Pharmaceuticals, For: Sep 30
High
Report
Form NT 10-Q TFF Pharmaceuticals, For: Sep 30
11/14
04:17 pm
tffp
Form 8-K TFF Pharmaceuticals, For: Nov 14
High
Report
Form 8-K TFF Pharmaceuticals, For: Nov 14
11/14
03:38 pm
tffp
Form SC 13G TFF Pharmaceuticals, Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G TFF Pharmaceuticals, Filed by: ARMISTICE CAPITAL, LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/15
TFF Pharmaceuticals Announces Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for use of its Thin Film Freezing Technology Platform
8.8%
1/28 TFF Pharmaceuticals Reports Continued Progress Across Programs in Corporate Update 6.8%
4/29 Form 10-K/A TFF Pharmaceuticals, For: Dec 31 6.7%
3/19 TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress for Voriconazole Inhalation Powder to Treat Invasive Pulmonary Aspergillosis (IPA) 4.3%
4/30 TFF Pharmaceuticals’ Inventor Dr. Robert O. Williams III Presents Session on Repurposing Niclosamide for COVID-19 Treatment at AAPS Meeting 2.8%
3/26 Form 8-K TFF Pharmaceuticals, For: Mar 26 2.6%
4/25 TFF Pharmaceuticals (NASDAQ: TFFP) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.25 price target on the stock. 2.5%
4/17 Form 4 TFF Pharmaceuticals, For: Apr 15 Filed by: Fletcher Aaron G.L. 2.3%
4/8 TFF Pharmaceuticals (NASDAQ: TFFP) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.0%
11/19 TFF Pharmaceuticals Selects LaVoieHealthScience as Investor Relations and Corporate Communications Partner 1.8%
1/28 TFF Pharmaceuticals Reports Continued Progress Across Programs in Corporate Update 6.8%
4/29 Form 10-K/A TFF Pharmaceuticals, For: Dec 31 6.7%
3/19 TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress for Voriconazole Inhalation Powder to Treat Invasive Pulmonary Aspergillosis (IPA) 4.3%
4/30 TFF Pharmaceuticals’ Inventor Dr. Robert O. Williams III Presents Session on Repurposing Niclosamide for COVID-19 Treatment at AAPS Meeting 2.8%
3/26 Form 8-K TFF Pharmaceuticals, For: Mar 26 2.6%
4/25 TFF Pharmaceuticals (NASDAQ: TFFP) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.25 price target on the stock. 2.5%
4/17 Form 4 TFF Pharmaceuticals, For: Apr 15 Filed by: Fletcher Aaron G.L. 2.3%
4/8 TFF Pharmaceuticals (NASDAQ: TFFP) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.0%
11/19 TFF Pharmaceuticals Selects LaVoieHealthScience as Investor Relations and Corporate Communications Partner 1.8%
TOP News Decliners
3/9
TFF Pharmaceuticals Announces Engagement of Torreya Partners, LLC as Strategic Advisor for Partnering Efforts in China and South Korea
-11.1%
3/23 TFF Pharmaceuticals Reschedules Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call for March 26, 2020 to 4:30 PM (EDT) -7.8%
4/6 Form 4 TFF Pharmaceuticals, For: Apr 02 Filed by: Fletcher Aaron G.L. -4.0%
12/17 Form 8-K TFF Pharmaceuticals, For: Dec 17 -2.7%
10/24 TFF Pharmaceuticals Prices $22 Million Public Offering of Common Stock -2.3%
4/17 TFF Pharmaceuticals to Present at April 2020 Virtual Investor Summit -2.0%
1/31 Form 8-K TFF Pharmaceuticals, For: Jan 27 -1.9%
4/1 TFF Pharmaceuticals (NASDAQ: TFFP) had its "buy" rating re-affirmed by analysts at Roth Capital. -1.3%
11/25 TFF Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Voriconazole Inhalation Powder, to Treat Invasive Pulmonary Aspergillosis (IPA) -1.2%
4/9 TFF Pharmaceuticals Announces R&D Collaboration with the University of Georgia for a Universal Influenza Vaccine -1.0%
3/23 TFF Pharmaceuticals Reschedules Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call for March 26, 2020 to 4:30 PM (EDT) -7.8%
4/6 Form 4 TFF Pharmaceuticals, For: Apr 02 Filed by: Fletcher Aaron G.L. -4.0%
12/17 Form 8-K TFF Pharmaceuticals, For: Dec 17 -2.7%
10/24 TFF Pharmaceuticals Prices $22 Million Public Offering of Common Stock -2.3%
4/17 TFF Pharmaceuticals to Present at April 2020 Virtual Investor Summit -2.0%
1/31 Form 8-K TFF Pharmaceuticals, For: Jan 27 -1.9%
4/1 TFF Pharmaceuticals (NASDAQ: TFFP) had its "buy" rating re-affirmed by analysts at Roth Capital. -1.3%
11/25 TFF Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Voriconazole Inhalation Powder, to Treat Invasive Pulmonary Aspergillosis (IPA) -1.2%
4/9 TFF Pharmaceuticals Announces R&D Collaboration with the University of Georgia for a Universal Influenza Vaccine -1.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: